Work

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9515

Authors: Adi Diab, Shah Rahimian, Cara L. Haymaker, Chantale Bernatchez, Robert Hans Ingemar Andtbacka, Marihella James, Douglas Buckner Johnson, Joseph Markowitz, Ravi Murthy, Igor Puzanov, Montaser F. Shaheen, Suzanne Swann

Institutions: The University of Texas MD Anderson Cancer Center, Idera Pharmaceuticals (United States), Huntsman Cancer Institute, Vanderbilt University Medical Center, The Ohio State University Wexner Medical Center, UNM Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891275440

Cites:

Cited by: 23

Related to: 10